According to the latest data from the Hong Kong Stock Exchange, on September 24, a MICROPORT (00853) shareholder transferred shares from Citibank to SBI International Securities, with a transfer value of HK$1.857 billion, representing 7.40% of the company's shares.

Morgan Stanley released a research report stating that MICROPORT faces ongoing domestic regulatory challenges, but demonstrates strong export momentum in surgical robotics (Medbot), cardiovascular, and vascular intervention businesses, with expectations to achieve break-even by 2026. Given that the cardiac rhythm management (CRM) obligations have been resolved and major shareholder Otsuka has completed its exit, the firm raised its target price from the previous HK$8.6 to HK$16, equivalent to approximately 20 times the projected 2027 price-to-earnings ratio. The "In-line" rating is maintained.